BioCardia (BCDA) Competitors

Mersana Therapeutics (NASDAQ:MRSN) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Does the media favor MRSN or BCDA?

In the previous week, BioCardia had 1 more articles in the media than Mersana Therapeutics. MarketBeat recorded 2 mentions for BioCardia and 1 mentions for Mersana Therapeutics. BioCardia's average media sentiment score of 1.43 beat Mersana Therapeutics' score of 0.47 indicating that BioCardia is being referred to more favorably in the news media.

Company	Overall Sentiment
Mersana Therapeutics	Neutral
BioCardia	Positive

Does the MarketBeat Community prefer MRSN or BCDA?

Mersana Therapeutics received 240 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 66.58% of users gave Mersana Therapeutics an outperform vote while only 60.71% of users gave BioCardia an outperform vote.

Company	Underperform	Outperform
Mersana Therapeutics	Outperform Votes 257 66.58%	Underperform Votes 129 33.42%
BioCardia	Outperform Votes 17 60.71%	Underperform Votes 11 39.29%

Do analysts prefer MRSN or BCDA?

Mersana Therapeutics presently has a consensus price target of $5.20, suggesting a potential upside of 1,322.32%. BioCardia has a consensus price target of $25.00, suggesting a potential upside of 1,011.11%. Given Mersana Therapeutics' higher possible upside, equities analysts plainly believe Mersana Therapeutics is more favorable than BioCardia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mersana Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
BioCardia	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Do insiders and institutionals have more ownership in MRSN or BCDA?

93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by insiders. Comparatively, 20.0% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has more volatility and risk, MRSN or BCDA?

Mersana Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.

Is MRSN or BCDA more profitable?

Mersana Therapeutics has a net margin of -214.20% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat Mersana Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mersana Therapeutics	-214.20%	-401.37%	-38.61%
BioCardia	-1,999.77%	N/A	-208.38%

Which has better earnings and valuation, MRSN or BCDA?

BioCardia has lower revenue, but higher earnings than Mersana Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mersana Therapeutics	$34.01M	1.34	-$171.67M	-$0.59	-0.62
BioCardia	$3K	3,883.50	-$11.57M	-$2.33	-0.97

Summary

Mersana Therapeutics beats BioCardia on 10 of the 18 factors compared between the two stocks.